Trial Profile
A Phase II Evaluation of SU11248 (Sunitinib Malate) (IND 74019, NSC 736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Clear cell sarcoma; Ovarian cancer
- Focus Therapeutic Use
- 06 Feb 2020 Status changed from active, no longer recruiting to completed.
- 16 Jun 2018 Results (n=35) published in the Gynecologic Oncology.
- 21 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.